The COVID vaccine brought a renewed public debate around vaccines. A new film airing on PBS explores the politicization of ...

EPS of $2.37 on $1.29 billion in sales, citing strong global demand for sleep devices, plus a boost from tariff exemptions.

Whooping cough cases are rising, and doctors are bracing for yet another tough year. There have been 8,485 cases reported in ...

Long a lobbying powerhouse in Washington, pharma’s struggling to settle on a strategy for defending itself, according to six industry lobbyists and three company officials who spoke to POLITICO. All ...

Here’s what several large drugmakers said about tariffs when reporting earnings this morning: Merck made a small downward ...

Recent US news is marked by upheaval in governmental bodies and key policy shifts. This includes significant firings in the ...

A middle school student north of Dallas has tested positive. Meanwhile, Illinois has confirmed its first case in the state. Plus: A study in mice shows that covid is still contagious a week or more ...

The FDA is asking Novavax for a non-mandatory postmarketing commitment to produce additional clinical data for its ...

Thousands of Americans campaigning for the Novavax COVID-19 booster got some good news this week: the FDA signaled it might ...

The FDA is considering the approval of the Novavax COVID-19 booster after delays amid controversy over its non-mRNA design.

At FDA, full vaccine approval is the gold standard. The agency was on track to sign off on Novavax’s license by its April 1 ...

Novavax's COVID-19 vaccine showed fewer side effects than Pfizer's in a Utah study as FDA seeks more data before full ...